Chapter 4
Unveiling Haloperidol’s Impact: A Case Report on Induced Parkinsonism and Extrapyramidal Symptoms
- By Abhishek Anand, Mithul V Mammen, Amit Kumar, Ayush Mishra, Abhishek Suman - 26 Sep 2025
- Emerging Trends in Pharmaceutical Sciences and Clinical Studies, Volume: 1, Pages: 18 - 19
Abstract/Preface
The onset of a parkinsonian condition in individuals receiving medication that inhibits dopaminergic transmission is the hallmark of Drug induced Parkinson [1]. After Parkinson’s disease drug-induced Parkinsonism is the second most common underlying cause of Parkinsonism in the elderly [2]. Haloperidol a neuroleptic medication, is one of the primary causes of drug-induced Parkinson’s disease in the global. One first-generation antipsychotic that is frequently used to treat schizophrenia is haloperidol [3]. Due to its propensity to cause a number of extrapyramidal symptoms, including tardive dyskinesia and Parkinsonism, haloperidol’s use is restricted. The precise aetiology of extrapyramidal symptoms brought on by haloperidol is still unknown [4]. Dopamine turnover rate rises as a result of dopamine receptor blockade brought on by Haloperidol treatment. Because of this, Reactive Oxygen Species may be produced as metabolic by products [5, 6]. Apart from generating free radicals, the ingestion of Haloperidol is linked to a notable reduction in the levels of the antioxidant glutathione [7].